| Beverly C Prince, MD | |
|
1001 East Second Street, Coudersort, PA 16915-8161 | |
| (814) 274-9300 | |
| Not Available |
| Full Name | Beverly C Prince |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Location | 1001 East Second Street, Coudersort, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912973314 | NPI | - | NPPES |
| 040046857 | Other | RAILROAD | |
| P010139747 | Other | BCBS ROCHESTER ROCH BLUES | |
| 1397470B | Other | WORMANS COMP | |
| 000914181003 | Other | BUFFALO BLUES | |
| 08842108 | Other | N AMERICAN PREFERRED | |
| MDG998 | Other | PREFERRED CARE | |
| P010139747 | Other | BLUE CHOICE | |
| 000914181003 | Other | COMMUNITY BLUE | |
| 00869163 | Medicaid | NY | |
| 00040440802 | Other | UNIVERA | |
| 0699696 | Other | GHI | |
| 1011404 | Other | IND HEALTH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | AP3043914 (New York) | Primary |
| Entity Name | Ellis Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487644993 PECOS PAC ID: 5890607410 Enrollment ID: O20031103000406 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago
| Entity Name | Hemant Patel Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750304978 PECOS PAC ID: 3971608522 Enrollment ID: O20070410000659 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago
| Entity Name | Auburn Memorial Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194913749 PECOS PAC ID: 6406931385 Enrollment ID: O20080318000053 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago
| Entity Name | Harlem Medical Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487957692 PECOS PAC ID: 9335321223 Enrollment ID: O20110315000005 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago
| Entity Name | Metropolitan Medical Practice Plan Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306138383 PECOS PAC ID: 8022286384 Enrollment ID: O20110713000171 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago
| Entity Name | Fatima Pediatric Medical Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295896744 PECOS PAC ID: 3577728419 Enrollment ID: O20120627000622 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago
| Entity Name | Empire Wound Physician Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093130742 PECOS PAC ID: 6406170497 Enrollment ID: O20150122001257 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Beverly C Prince, MD 1001 East Second Street, Coudersort, PA 16915-8161 Ph: (814) 274-9300 | Beverly C Prince, MD 1001 East Second Street, Coudersort, PA 16915-8161 Ph: (814) 274-9300 |
News Archive
The full implementation of traditional public health control strategies and integration of new regulatory authorities has the potential to significantly reduce tobacco-related deaths in the U.S., according to experts at the George Washington University School of Medicine and Health Sciences and the Center for Tobacco Products at the Food and Drug Administration.
It's well known that a relatively small percentage of chronically ill patients account for a disproportionate amount of health care dollars. Now, a multicenter study led by Johns Hopkins researcher Bruce Leff, M.D., might provide insights into how to cut Medicare costs while improving health care for older adults suffering from chronic health conditions.
New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world's first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.
› Verified 7 days ago